Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS
Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.
You may also be interested in...
Eurordis head Yann Le Cam outlines his vision for the future of orphan drug pricing in Europe.
"It's time for industry and payers to start thinking about different pricing models, and it's going to require some transparency about what everything costs," said Sir Andrew Witty, speaking to Scrip on 18 April. "Lots of people will say pricing is not an issue in oncology. It's going to be an issue – it's inevitable."
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.